Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs

被引：14

作者：

Nakai, Hidekatsu ^{[1
]}

Matsumura, Noriomi ^{[1
]}

机构：

[1] Kindai Univ, Fac Med, Dept Obstet & Gynecol, 377-2 Ohnohigashi, Osaka, Osaka 5898511, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 27卷 / 06期

关键词：

Ovarian cancer; Molecularly targeted drug; PARP inhibitor; OLAPARIB PLUS BEVACIZUMAB; NIRAPARIB MAINTENANCE THERAPY; ADVANCED EPITHELIAL OVARIAN; FALLOPIAN-TUBE; PATIENTS PTS; EFFICACY; PACLITAXEL; SURVIVAL; CHEMOTHERAPY; CARBOPLATIN;

D O I：

10.1007/s10147-022-02163-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the development of poly(ADP-ribose) polymerase inhibitors, the treatment of advanced ovarian cancer is changing dramatically. The purpose of this narrative review is to provide a direction for the individualization of advanced ovarian cancer treatment based on the mechanism of action of molecularly targeted drugs currently used in Japan. The PAOLA-1 study showed very good progression-free survival in patients with homologous recombination deficiency tumors who underwent complete surgery with primary debulking surgery and who received olaparib plus bevacizumab. Niraparib has high intratumor penetration, and in a subgroup analysis of the PRIMA study, it was most effective in patients with residual tumors after interval debulking surgery. These data suggest the importance of achieving complete surgery and aiming for cure in the treatment of ovarian cancer and how the use of bevacizumab, olaparib, and niraparib should be individualized.

引用

页码：1001 / 1012

页数：12

共 52 条

[1]

[Anonymous], 2021, ZEJULA GUIDE APPROPR

[2] Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Banerjee, Susana ;

Moore, Kathleen N. ;

Colombo, Nicoletta ;

Scambia, Giovanni ;

Kim, Byoung-Gie ;

Oaknin, Ana ;

Friedlander, Michael ;

Lisyanskaya, Alla ;

Floquet, Anne ;

Leary, Alexandra ;

Sonke, Gabe S. ;

Gourley, Charlie ;

Oza, Amit ;

Gonzalez-Martin, Antonio ;

Aghajanian, Carol ;

Bradley, William H. ;

Holmes, Eileen ;

Lowe, Elizabeth S. ;

DiSilvestro, Paul .

LANCET ONCOLOGY, 2021, 22 (12) :1721-1731

[3] P-glycoprotein ABCB1: a major player in drug handling by mammals [J].

Borst, Piet ;

Schinkel, Alfred H. .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (10) :4131-4133

[4] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[5] Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment [J].

Chan, Norman ;

Pires, Isabel M. ;

Bencokova, Zuzana ;

Coackley, Carla ;

Luoto, Kaisa R. ;

Bhogal, Nirmal ;

Lakshman, Minalini ;

Gottipati, Ponnari ;

Oliver, F. Javier ;

Helleday, Thomas ;

Hammond, Ester M. ;

Bristow, Robert G. .

CANCER RESEARCH, 2010, 70 (20) :8045-8054

[6] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial [J].

Clamp, Andrew R. ;

James, Elizabeth C. ;

McNeish, Iain A. ;

Dean, Andrew ;

Kim, Jae-Weon ;

O'Donnell, Dearbhaile M. ;

Hook, Jane ;

Coyle, Christopher ;

Blagden, Sarah ;

Brenton, James D. ;

Naik, Raj ;

Perren, Tim ;

Sundar, Sudha ;

Cook, Adrian D. ;

Gopalakrishnan, Gosala S. ;

Gabra, Hani ;

Lord, Rosemary ;

Dark, Graham ;

Earl, Helena M. ;

Hall, Marcia ;

Banerjee, Susana ;

Glasspool, Rosalind M. ;

Jones, Rachel ;

Williams, Sarah ;

Swart, Ann Marie ;

Stenning, Sally ;

Parmar, Mahesh ;

Kaplan, Richard ;

Ledermann, Jonathan A. .

LANCET, 2019, 394 (10214) :2084-2095

[7] Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].

Coleman, R. L. ;

Fleming, G. F. ;

Brady, M. F. ;

Swisher, E. M. ;

Steffensen, K. D. ;

Friedlander, M. ;

Okamoto, A. ;

Moore, K. N. ;

Ben-Baruch, N. Efrat ;

Werner, T. L. ;

Cloven, N. G. ;

Oaknin, A. ;

DiSilvestro, P. A. ;

Morgan, M. A. ;

Nam, J. -H. ;

Leath, C. A., III ;

Nicum, S. ;

Hagemann, A. R. ;

Littell, R. D. ;

Cella, D. ;

Baron-Hay, S. ;

Garcia-Donas, J. ;

Mizuno, M. ;

Bell-McGuinn, K. ;

Sullivan, D. M. ;

Bach, B. A. ;

Bhattacharya, S. ;

Ratajczak, C. K. ;

Ansell, P. J. ;

Dinh, M. H. ;

Aghajanian, C. ;

Bookman, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415

[8] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial [J].

del Campo, Josep M. ;

Matulonis, Ursula A. ;

Malander, Susanne ;

Provencher, Diane ;

Mahner, Sven ;

Follana, Philippe ;

Waters, Justin ;

Berek, Jonathan S. ;

Woie, Kathrine ;

Oza, Amit M. ;

Canzler, Ulrich ;

Gil-Martin, Marta ;

Lesoin, Anne ;

Monk, Bradley J. ;

Lund, Bente ;

Gilbert, Lucy ;

Wenham, Robert M. ;

Benigno, Benedict ;

Arora, Sujata ;

Hazard, Sebastien J. ;

Mirza, Mansoor R. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2968-+

[9] Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial [J].

DiSilvestro, Paul ;

Colombo, Nicoletta ;

Scambia, Giovanni ;

Kim, Byoung-Gie ;

Oaknin, Ana ;

Friedlander, Michael ;

Lisyanskaya, Alla ;

Floquet, Anne ;

Leary, Alexandra ;

Sonke, Gabe S. ;

Gourley, Charlie ;

Banerjee, Susana ;

Oza, Amit ;

Gonzalez-Martin, Antonio ;

Aghajanian, Carol A. ;

Bradley, William H. ;

Mathews, Cara A. ;

Liu, Joyce ;

Lowe, Elizabeth S. ;

Bloomfield, Ralph ;

Moore, Kathleen N. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (30) :3528-+

[10] Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) [J].

du Bois, Andreas ;

Reuss, Alexander ;

Pujade-Lauraine, Eric ;

Harter, Philipp ;

Ray-Coquard, Isabelle ;

Pfisterer, Jacobus .

CANCER, 2009, 115 (06) :1234-1244

← 1 2 3 4 5 6 →